Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

Ionis Shares Pop As Aetna Adds Spinraza To Precertification List

Ionis Shares Pop As Aetna Adds Spinraza To Precertification List

Ionis Pharmaceuticals Inc (NASDAQ: IONS) shares were trading up 6.61 percent Tuesday on news that Aetna Inc (NYSE: AET) added Spinraza — a drug developed by Ionis and licensed by Biogen Inc (NASDAQ: BIIB) — to its precertification list.

However, an Aetna representative told Benzinga the “appearance on this list does not indicate one way or the other what the clinical policy will be.”

Related Article: Why Spinraza Is The Only Exciting Thing About Ionis Pharmaceuticals

“As with all new FDA-approved products, we will conduct a full clinical review of Spinraza (nusinersen) to determine our clinical coverage policy,” the spokesperson said. “We have not yet completed this review.”

In October, Benzinga received a similar response from Aetna regarding Sarepta Therapeutics Inc (NASDAQ: SRPT)’s Exondys 51, whose coverage was confirmed two months later.

Ionis shares traded around $49.95 at time of publication.

Posted-In: News Health Care FDA Legal Exclusives Interview General Best of Benzinga


Related Articles (BIIB + AET)

View Comments and Join the Discussion!

Vetr Issues Blackline A Strong Buy

Here's What The Pros Are Saying About Snap